NRP1 and EGFR were highly expressed in most cancer cells [52–58], and this suggests that PRV-LAV may have potential utility in personalized cancer therapy among patients with NRP1/EGFR-overexpressing tumors. The gene discussed is EGFR; the disease is cancer.